Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

InnoCare Pharma reports 55.5% revenue increase in H1 2026, stock falls nonetheless

InnoCare Pharma recorded a 55.5% revenue increase in the first half of 2026 to RMB 1.137 billion and returned to profit with a net income of RMB 240 million. The company reported positive operating cash flow and cash and equivalents of around RMB 8.4 billion, while continuing to invest RMB 497 million in R&D. Despite the strong metrics, the stock fell nearly 7% after the release, as management left the full-year guidance for drug sales growth unchanged at above 35% and said it would wait for Q3 trends before making further adjustments. » Altro su de.investing.com
InnoCare Pharma: phase‑3 study shows orelabrutinib reduces progression risk by 68% in CLL/SLL

A phase‑3 study published in Signal Transduction and Targeted Therapy shows that orelabrutinib reduces the risk of disease progression or death by 68% in treatment‑naive CLL/SLL patients versus chemoimmunotherapy and achieves an overall response rate of 90.1% versus 79.2%. Duration of response was markedly longer (hazard ratio 0.30), severe treatment‑related adverse events were less frequent, and no treatment‑related atrial fibrillation, major bleeding, or secondary primary malignancies were observed. Orelabrutinib is approved in China for first‑line therapy and was added to the national reimbursement list in 2025. Financial data report a market capitalization of USD 22.1 million, revenue of USD 41.4 million over the last twelve months, a gross margin of 38%, and a PEG of 0.26; the stock is trading near its 52‑week low, though analysts view it as undervalued. » Altro su de.investing.com
InnoCare launches phase‑1 study for oral IL‑17 inhibitor ICP‑054

InnoCare has dosed the first participant in a phase‑1 study of ICP‑054, an oral IL‑17AA/AF inhibitor. The trial will assess safety, tolerability and pharmacokinetics after single and multiple ascending doses in healthy volunteers. The study is being conducted in China in partnership with Zenas BioPharma, with results expected by the end of 2026. Zenas holds exclusive worldwide rights except for Greater China and Southeast Asia; InnoCare plans to advance clinical development to evaluate efficacy in autoimmune diseases thereafter. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, InnoCare Pharma ha già distribuito 0,22 € di dividendi. L'ultimo pagamento è avvenuto a luglio 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, InnoCare Pharma ha registrato ricavi pari a 78,14 Mln € e un utile netto di 18,05 Mln €

(EUR)	giu 2026	YoY
Ricavi	78,14 Mln	88,42%
Utile lordo	67,93 Mln	85,32%
Utile netto	18,05 Mln	417,11%
EBITDA	13,25 Mln	226,12%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	2,41 Mld €
Numero di azioni	1,49 Mld
Massimo/minimo a 52 settimane	2,22 € - 1,06 €
Dividendi	No
Beta	0,39
Rapporto P/E	24,22
Rapporto PEG	0,05
Rapporto P/B	2,89
Rapporto P/S	6,82

Profilo aziendale

InnoCare Pharma Limited, ein biopharmazeutisches Unternehmen, beschäftigt sich mit der Entdeckung, Entwicklung und Vermarktung von Medikamenten zur Behandlung von Krebs und Autoimmunkrankheiten. Es entwickelt Orelabrutinib, einen BTK-Inhibitor zur Behandlung von Patienten mit rezidivierter und/oder refraktärer (r/r) chronischer lymphatischer Leukämie, r/r Mantelzell-Lymphom, r/r Waldenstrom-Makroglobulinämie, r/r Marginalzonen-Lymphom, r/r diffuses großzelliges B-Zell-Lymphom (DLBCL) - MCD, r/r Lymphom des zentralen Nervensystems, Kombination mit MIL-62, systemischer Lupus erythematodes, Immunthrombozytopenie purpura, multiple Sklerose und Neuromyelitis optica-Spektrum-Störung. Das Unternehmen entwickelt außerdem ICP-192, einen pan-FGFR-Inhibitor, der sich in einer klinischen Phase I/II-Studie zur Behandlung von Patienten mit soliden Tumoren, einschließlich Cholangiokarzinom und Kopf- und Halskrebs, befindet; ICP-723, ein pan-TRK-Inhibitor, der sich in einer klinischen Phase-I-Studie zur Behandlung von neurotrophen Tyrosinrezeptor-Kinase-Fusions-positiven Krebserkrankungen befindet; ICP-332, ein neuartiger Tyrosinkinase-2-Inhibitor, der sich in einer klinischen Phase-I-Studie zur Behandlung von Autoimmunerkrankungen befindet; und ICP-B02, ein bispezifischer Antikörper zur Behandlung von Lymphomen. Darüber hinaus entwickelt das Unternehmen ICP-189, ICP-915 und ICP-B03 zur Behandlung von soliden Tumoren, ICP-033 zur Behandlung von Leberkrebs, Nierenzellkarzinom, Darmkrebs und anderen soliden Tumoren, ICP-488 zur Behandlung von Autoimmunerkrankungen, ICP-B05, einen monoklonalen Antikörper gegen den CC-Chemokinrezeptor 8 zur Behandlung verschiedener Krebsarten, ICP-248 zur Behandlung von Hämatologie und ICP-490 zur Behandlung von Hämatologie und Autoimmunerkrankungen. Außerdem bietet das Unternehmen ICP-B04 (Tafasitamab) zur Behandlung von DLBCL/Hämatologie an. InnoCare Pharma Limited wurde 2015 gegründet und hat seinen Hauptsitz in Peking, China.